Ontology highlight
ABSTRACT:
SUBMITTER: Byon W
PROVIDER: S-EPMC5445237 | biostudies-literature | 2017 May
REPOSITORIES: biostudies-literature
Byon W W Sweeney K K Frost C C Boyd R A RA
CPT: pharmacometrics & systems pharmacology 20170501 5
Apixaban is approved for treatment of venous thromboembolism (VTE) and prevention of recurrence. Population pharmacokinetics, pharmacokinetics-pharmacodynamics (anti-FXa activity), and exposure-response (binary bleeding and thromboembolic endpoints) of apixaban in VTE treatment subjects were characterized using data from phase I-III studies. Apixaban pharmacokinetics were adequately characterized by a two-compartment model with first-order absorption and elimination. Age, sex, and Asian race had ...[more]